Comparative Pharmacology
Head-to-head clinical analysis: COLESTID versus COLESTIPOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESTID versus COLESTIPOL HYDROCHLORIDE.
COLESTID vs COLESTIPOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
5-10 g orally once or twice daily, maximum 30 g/day.
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
None Documented
None Documented
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant